Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Jan 20;9:4. doi: 10.1186/1471-2334-9-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2009 Eichner et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Comparison of de novo development of resistance and importation of resistance. Prevalence of infection with drug sensitive (solid curves) and drug resistant infection (dashed curves) during a pandemic wave in a population of 100,000 inhabitants. Scenario (a): a drug-sensitive infection is introduced on day 0; NI resistant infection develops de novo during antiviral treatment of cases throughout the simulation (treatment parameters see Figure 2; no prophylaxis; 100% fitness of the resistant virus; black curves). Scenario (b): the importation of a drug sensitive infection on day 0 is followed by an importation of a NI resistant infection on day 28. Treatment is given as in scenario (a), but no de novo development of resistance occurs within this scenario (grey curves). The resulting curves for Scenario (a) and (b) are nearly indistinguishable.